LAG3 and cervical carcinoma: A key immune checkpoint gene, LAG3, was successfully screened and identified, which provides an important theoretical basis and a new idea for the development of novel immunotherapeutic drugs based on the LAG3 target (e.g., LAG3 inhibitor monotherapy or combination therapy) for cervical cancer.